08.04.2013 - AstraZeneca's arthritis pill fostamatinib is proven inferior to competitor drugs in a late-stage clinical trial.
While the first-in-class oral rheumatoid (RA) arthritis drug proved to be efficient as measured by ACR20 reponse it failed to halt the progression of joint damage as compared with placebo in the OSKIRA-1 Phase III study. In December, fastamatinib was shown to be inferior in efficacy compared to Abbvie’s injectible RA blockbuster antibody Humira (adalimumab),reducing its ability to compete in the US$20bn-plus RA market. AstraZeneca’ RA pill also increased blood pressure and led to diarrhea.
"Our misgiving is that fostamatinib appears to be inferior to Humira on efficacy and now the adverse events seem to pitch it below Pfizer's Xeljanz, (– another RA pill in late-stage development –) so it is hard to see where the product will fit," said Panmure Gordon analyst Savvas Neophytou.
AstraZeneca, which currently announced the restructuring of its R&D, licensed fostamatinib in 2010 from Rigel Pharmaceuticals. However, after the current study results, analysts forecasted only low fostamatinib sales, averaging just US$171m in 2016. Humira, by contrast, has annual worldwide sales of more than $9 billion but has become under pressure by new RA drugs such as Roche’s RoActemra.
With last year's loss of exclusivity on schizophrenia drug Seroquel, and Nexium for stomach acid and cholesterol fighter Crestor set for U.S. patent expiries in 2014 and 2016, AstraZeneca faces one of the industry's steepest "cliffs" of patent expiries.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more